ABSTRACT. Point-of-care (POC) tests to detect SARS-CoV-2 antibodies offer quick assessment of serostatus after natural infection or vaccination. We compared the field performance of the BioMedomics COVID-19 IgM/IgG Rapid Antibody Test against an ELISA in 303 participants enrolled in a SARS-CoV-2 household cohort study. The rapid antibody test was easily implemented with consistent interpretation across 14 users in a variety of field settings. Compared with ELISA, detection of seroconversion lagged by 5 to 10 days. However, it retained a sensitivity of 90% (160/177, 95% confidence interval [CI] 85–94%) and specificity of 100% (43/43, 95% CI 92–100%) for those tested 3 to 5 weeks after symptom onset. Sensitivity was diminished among those with asymptomatic infection (74% [14/19], 95% CI 49–91%) and early in infection (45% [29/64], 95% CI 33–58%). When used appropriately, rapid antibody tests offer a convenient way to detect symptomatic infections during convalescence.
【초록키워드】 COVID-19, SARS-CoV-2, rapid antibody test, vaccination, POC, Infection, Test, ELISA, cohort study, sensitivity, specificity, Seroconversion, SARS-CoV-2 antibodies, SARS-CoV-2 antibody, IgM/IgG, antibody tests, Interpretation, asymptomatic infection, Rapid, convalescence, Antibody test, natural infection, serostatus, symptomatic infection, Rapid antibody tests, symptom onset, 95% CI, 95% confidence interval, participant, offer, symptomatic infections, enrolled, tested, detect, variety, retained, 【제목키워드】 SARS-CoV-2, Test, household, Rapid, assessment, field,